Insulin resistance and hypertension

Clinical and Experimental Hypertension

Volumn 21, Issue 5-6, 1999, Pages 885-894

  Landsberg, Lewis ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Blood pressure; Insulin; Lipids; Sympathetic nervous system

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; INSULIN; LISINOPRIL; THIAZIDE DIURETIC AGENT;

ADRENERGIC SYSTEM; BEHAVIOR MODIFICATION; CONFERENCE PAPER; CORONARY RISK; DIET THERAPY; ESSENTIAL HYPERTENSION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KINESIOTHERAPY; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK FACTOR; SYNDROME X; WEIGHT REDUCTION;

EID: 0032791094     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969909061017     Document Type: Conference Paper

References (23)

1. Reaven GM, Lithell H, Landsberg L. Hypertension and Associated Metabolic Abnormalities - The Role of Insulin Resistance and the Sympathoadrenal System. N Engl Journal of Medicine 1996;334:374-381.
2. Kennedy A, Gettys TW, Watson P, et al. The Metabolic Significance of Leptin in Humans: Gender-Based Differences in Relationship to Adiposity, Insulin Sensitivity, and Energy Expenditure. J Clin Endocrinol Metab 1997;82:1293-1300.
3. Shek EW, Brands MW, Hall JE. Chronic Leptin Infusion Increases Arterial Pressure. Hypertension 1998;31[part 2]:409-414.
4. Haynes WG, Morgan DA, Walsh SA, et al. Receptor-mediated Regional Sympathetic Nerve Activation by Leptin. J. Clin. Invest. 1997; 100:270-278.
5. Dunbar JX, Hu Y, Lu H. Intracerebroventricular Leptin Increases Lumbar and Renal Sympathetic Nerve Activity and Blood Pressure in Normal Rats. Diabetes 1997;46:2040-2043.
6. Agata J, Masuda A, Takada M, et al. High Plasma Immunoreactive Leptin Level in Essential Hypertension. Am J Hypertens 1997;10:1171-1174.
7. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link between hypertension, obesity, and glucose tolerance. J Clin Invest 1985;75:809-817.
8. Nilsson PM, Lind L, Andersson PE, et al. On the use of ambulatory blood pressure recordings and insulin sensitivity measurements in support of the insulin-hypertension hypothesis. J Hypertens 1994; 12(8)965-969.
9. Kamide K, Rakugi H, Nakano N, et al. Insulin Resistance Is Related to Silent Cerebral Infarction in Patients With Essential Hypertension. Am J Hypertens 1997;10:1245-1249.
10. Lind L, Berne C, Andersson PE, et al. Is insulin resistance a predictor of the blood pressure response to anti-hypertensive treatment? Journal of Human Hypertension 1995;9:759-763.
11. Weir MR, Reisin E, Falkner B, et al. Nocturnal Reduction of Blood Pressure and the Antihypertensive Response to a Diuretic or Angiotensin Converting Enzyme Inhibitor in Obese Hypertensive Patients. Am J Hypertens 1998;11:914-920.
12. Reisin E, Weir MR, Falkner B, et al. Lisinopril Versus Hydrochlorothiazide in Hypertensive Patients A Multicenter Placebo-Controlled Trial. Hypertension 1997;30[part 1]:140-145.
13. Lithell HO. Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism. Diabetes Care 1991;14:203-209.
14. Lithell HO. Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. Journal of Hypertension 1997;15 (suppl 1):S39-S42.
15. Grimm RH, Flack JM, Grandits GA, et al. Long-term Effects on Plasma Lipids of Diet and Drugs to Treat Hypertension. JAMA 1996;275:1549-1556.
16. Bönner G, Schmieder R, Chrosch R, Weidinger G. Effect of Bunazosin and Atenolol on Glucose Metabolism in Obese, Nondiabetic Patients with PrimaryHypertension. Cardiovasc Drugs Ther 1997;11:21 -26.
17. Morel Y, Gadient A, Keller U, et al. Insulin Sensitivity in Obese Hypertensive Dyslipidemic Patients Treated with Enalapril or Atenolol. Journal of Cardiovascular Pharmacology 1995;26:306-311.
18. Suzuki M, Ikebuchi M, Yokota C, et al. Normalization of Insulin Resistance in Non-Obese Essential Hypertension by Cilazapril Treatment. Clin, and Exper. Hypertension 1995;17(8), 1257-1268.
19. Böhlen L, Bienz R, Doser M, et al. Metabolic Neutrality of Perindopril: Focus on Insulin Sensitivity in Overweight Patients with Essential Hypertension. Journal of Cardiovascular Pharmacology 1996;27:770-776.
20. Reaven GM, Clinkingbeard C. Jeppesen J, et al. Comparison of the Hemodynamic and Metabolic Effects of Low-Dose Hydrochlorothiazide and Lisinopril Treatment in Obese Patients with High Blood Pressure. Am J Hypertens 1995;8:461-466.
21. Nilsson P. New drugs and clinical trials in diabetes and hypertension. Exp Clin Endocrinol Diabetes 105 (1997) Suppl 2.
22. Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of Insulin Sensitivity by Tyroglitazone Lowers Blood Pressure in Diabetic Hypertensives. AJH Mar 1995;8:p316-320.
23. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.